Cargando…
Combinations of an acetyl CoA carboxylase inhibitor with hepatic lipid modulating agents do not augment antifibrotic efficacy in preclinical models of NASH and fibrosis
Dysregulated hepatocyte lipid metabolism is a hallmark of hepatic lipotoxicity and contributes to the pathogenesis of nonalcoholic steatohepatitis (NASH). Acetyl CoA carboxylase (ACC) inhibitors decrease hepatocyte lipotoxicity by inhibiting de novo lipogenesis and concomitantly increasing fatty aci...
Autores principales: | Vijayakumar, Archana, Okesli‐Armlovich, Ayse, Wang, Ting, Olson, Isabel, Seung, Minji, Kusam, Saritha, Hollenback, David, Mahadevan, Sangeetha, Marchand, Bruno, Toteva, Maria, Breckenridge, David G., Trevaskis, James L., Bates, Jamie |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9426400/ https://www.ncbi.nlm.nih.gov/pubmed/35735253 http://dx.doi.org/10.1002/hep4.2011 |
Ejemplares similares
-
Acetyl-CoA Carboxylase Inhibition Improves Multiple Dimensions of NASH Pathogenesis in Model Systems
por: Ross, Trenton T., et al.
Publicado: (2020) -
Acetyl-CoA Carboxylases and Diseases
por: Wang, Yu, et al.
Publicado: (2022) -
WZ66, a novel acetyl-CoA carboxylase inhibitor, alleviates nonalcoholic steatohepatitis (NASH) in mice
por: Gao, Ying-sheng, et al.
Publicado: (2019) -
Chemical Genetics of Acetyl-CoA Carboxylases
por: Zu, Xuyu, et al.
Publicado: (2013) -
Acetyl-CoA carboxylase inhibitor increases LDL-apoB production rate in NASH with cirrhosis: prevention by fenofibrate
por: Dandan, Mohamad, et al.
Publicado: (2023)